-
Je něco špatně v tomto záznamu ?
Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors
A. Šafanda, M. Kendall Bártů, R. Michálková, I. Stružinská, J. Drozenová, P. Fabián, J. Hausnerová, J. Laco, R. Matěj, P. Škapa, M. Švajdler, Z. Špůrková, G. Méhes, P. Dundr, K. Němejcová
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
Grantová podpora
NV19-03-00007
Ministerstvo Zdravotnictví Ceské Republiky
NLK
ProQuest Central
od 2003-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2003-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2003-01-01 do Před 1 rokem
- MeSH
- antigeny nádorové MeSH
- karcinom * patologie MeSH
- lidé MeSH
- melanom * MeSH
- nádorové biomarkery analýza MeSH
- nádory cystické, mucinózní a serózní * MeSH
- nádory vaječníků * MeSH
- serózní cystadenokarcinom * patologie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy.We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs.The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.
Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Pathology Bulovka Hospital Prague Czech Republic
Department of Pathology Faculty of Medicine University of Debrecen 4032 Debrecen Hungary
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24001155
- 003
- CZ-PrNML
- 005
- 20240213094409.0
- 007
- ta
- 008
- 240109s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00428-023-03629-z $2 doi
- 035 __
- $a (PubMed)37610627
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Šafanda, Adam $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 245 10
- $a Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors / $c A. Šafanda, M. Kendall Bártů, R. Michálková, I. Stružinská, J. Drozenová, P. Fabián, J. Hausnerová, J. Laco, R. Matěj, P. Škapa, M. Švajdler, Z. Špůrková, G. Méhes, P. Dundr, K. Němejcová
- 520 9_
- $a Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen selectively expressed in somatic tissues and various solid malignant tumors and is associated with poor prognostic outcome. Our research aimed to comprehensively compare its expression in a large cohort of tubo-ovarian epithelial tumors and examine its correlation with our clinico-pathologic data, as well as to assess its potential use in diagnostics and therapy.We examined 485 cases of epithelial tubo-ovarian tumors including 107 clear cell carcinomas (CCC), 52 endometroid carcinomas (EC), 103 high grade serous carcinomas (HGSC), 119 low grade serous carcinomas (LGSC)/micropapillary variant of serous borderline tumors (mSBT), and 104 cases of mucinous carcinomas (MC)/mucinous borderline tumors (MBT). The immunohistochemical analysis was performed using TMAs.The highest levels of expression were seen in EC (60%), HGSC (62%), and CCC (56%), while expression in LGSC/mSBT (4%) and MC/MBT (2%) was rare. The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory vaječníků $7 D010051
- 650 12
- $a nádory cystické, mucinózní a serózní $7 D018297
- 650 12
- $a karcinom $x patologie $7 D002277
- 650 12
- $a serózní cystadenokarcinom $x patologie $7 D018284
- 650 12
- $a melanom $7 D008545
- 650 _2
- $a nádorové biomarkery $x analýza $7 D014408
- 650 _2
- $a antigeny nádorové $7 D000951
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kendall Bártů, Michaela $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Michálková, Romana $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Stružinská, Ivana $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Drozenová, Jana $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic
- 700 1_
- $a Fabián, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Hausnerová, Jitka $u Department of Pathology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Laco, Jan $u The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Matěj, Radoslav $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic
- 700 1_
- $a Škapa, Petr $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Švajdler, Marián $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Špůrková, Zuzana $u Department of Pathology, Bulovka Hospital, Prague, Czech Republic
- 700 1_
- $a Méhes, Gábor $u Department of Pathology, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary
- 700 1_
- $a Dundr, Pavel $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Němejcová, Kristýna $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic. Kristyna.Nemejcova@vfn.cz $1 https://orcid.org/0000000193409320 $7 xx0233214
- 773 0_
- $w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 483, č. 4 (2023), s. 509-516
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37610627 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213094406 $b ABA008
- 999 __
- $a ok $b bmc $g 2049638 $s 1210849
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 483 $c 4 $d 509-516 $e 20230823 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
- GRA __
- $a NV19-03-00007 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20240109
